Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.
作者信息
Shimabukuro Tom T, Cole Matthew, Su John R
机构信息
Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
出版信息
JAMA. 2021 Mar 16;325(11):1101-1102. doi: 10.1001/jama.2021.1967.
Abstract
摘要
相似文献
1
Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.
JAMA. 2021 Mar 16;325(11):1101-1102. doi: 10.1001/jama.2021.1967.
2
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129. doi: 10.15585/mmwr.mm7004e1.
3
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.
4
Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.
Am J Transplant. 2021 Mar;21(3):1326-1331. doi: 10.1111/ajt.16517.
5
Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020.
Am J Transplant. 2021 Mar;21(3):1332-1337. doi: 10.1111/ajt.16516.
6
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.
JAMA. 2021 Feb 23;325(8):780-781. doi: 10.1001/jama.2021.0600.
7
Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States.
Ann Allergy Asthma Immunol. 2021 Jul;127(1):139-140. doi: 10.1016/j.anai.2021.04.004. Epub 2021 Apr 8.
8
COVID vaccines and safety: what the research says.
Nature. 2021 Feb;590(7847):538-540. doi: 10.1038/d41586-021-00290-x.
9
First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):283-288. doi: 10.15585/mmwr.mm7008e3.
10
Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
Drug Saf. 2021 Nov;44(11):1209-1214. doi: 10.1007/s40264-021-01104-9. Epub 2021 Aug 4.
引用本文的文献
1
Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study.
Trop Dis Travel Med Vaccines. 2025 Aug 14;11(1):30. doi: 10.1186/s40794-025-00266-z.
2
Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects.
Support Care Cancer. 2025 Aug 4;33(8):753. doi: 10.1007/s00520-025-09783-1.
3
The Application of Single-Cell Technologies for Vaccine Development Against Viral Infections.
Vaccines (Basel). 2025 Jun 26;13(7):687. doi: 10.3390/vaccines13070687.
4
Nanotechnology Approaches for Mitigating Biologic Immunogenicity: A Literature Review.
Pharmaceutics. 2025 Jul 7;17(7):888. doi: 10.3390/pharmaceutics17070888.
5
National Pharmacovigilance Assessment of Oral Adverse Events Following COVID-19 Vaccination in Germany (2020-2023).
Int Dent J. 2025 Jul 19;75(5):100906. doi: 10.1016/j.identj.2025.100906.
6
The Future of mRNA Vaccines: Potential Beyond COVID-19.
Cureus. 2025 May 21;17(5):e84529. doi: 10.7759/cureus.84529. eCollection 2025 May.
7
Enhancing RNA vaccine safety through localized delivery strategies.
Vaccine Insights. 2025 Mar;4(2):41-45. Epub 2025 Mar 20.
8
The Application of mRNA Technology for Vaccine Production-Current State of Knowledge.
Vaccines (Basel). 2025 Apr 4;13(4):389. doi: 10.3390/vaccines13040389.
9
COVID-19 mRNA-1273 vaccination induced mast cell activation with strongly elevated Th cytokines in a systemic mastocytosis patient.
Inflamm Res. 2025 Apr 29;74(1):71. doi: 10.1007/s00011-025-02032-5.
10
Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines.
Vaccines (Basel). 2025 Mar 10;13(3):289. doi: 10.3390/vaccines13030289.
本文引用的文献
1
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129. doi: 10.15585/mmwr.mm7004e1.
2
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.
JAMA. 2021 Feb 23;325(8):780-781. doi: 10.1001/jama.2021.0600.
3
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.
MMWR Morb Mortal Wkly Rep. 2021 Jan 1;69(5152):1653-1656. doi: 10.15585/mmwr.mm695152e1.
4
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924. doi: 10.15585/mmwr.mm6950e2.
5
Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity - United States, January 26-October 3, 2020.
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1522-1527. doi: 10.15585/mmwr.mm6942e2.
6
Vaccine-associated hypersensitivity.
J Allergy Clin Immunol. 2018 Feb;141(2):463-472. doi: 10.1016/j.jaci.2017.12.971.
7
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22.
8
Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
Vaccine. 2007 Aug 1;25(31):5675-84. doi: 10.1016/j.vaccine.2007.02.064. Epub 2007 Mar 12.
Zotero 插件